Xuanzhu Biopharmaceutical (02575.HK) is an innovative drug subsidiary controlled by Sihuan Pharmaceutical, a major domestic pharmaceutical group. The company focuses on multiple therapeutic areas including oncology, gastroenterology, and metabolism. It is one of the few innovative drug enterprises in China with a fully integrated industrial chain spanning R&D, manufacturing, and sales across both large and small molecule fields, while maintaining complete independent intellectual property rights. On October 15, 2025, Xuanzhu Biopharmaceutical was listed on the Hong Kong Stock Exchange. Efung Capital invested in the company in 2021.